CBT
NBIX icon

Capital Bank & Trust’s Neurocrine Biosciences NBIX Stock Holding History

Capital Bank & Trust’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-119,922
Closed -$11.7M – 128
2021
Q2 		$11.7M Sell
119,922
-1,078
-0.9% -$103K 0.14% 124
2021
Q1 		$11.8M Sell
121,000
-108,880
-47% -$11.4M 0.14% 124
2020
Q4 		$22M Sell
229,880
-2,354
-1% -$227K 0.27% 93
2020
Q3 		$22.3M Sell
232,234
-46,128
-17% -$5.34M 0.3% 84
2020
Q2 		$34M Buy
278,362
+1,615
+0.6% +$178K 0.5% 59
2020
Q1 		$24M Sell
276,747
-12,418
-4% -$1.22M 0.4% 69
2019
Q4 		$31.1M Sell
289,165
-2,617
-0.9% -$274K 0.4% 72
2019
Q3 		$26.3M Sell
291,782
-31,032
-10% -$2.9M 0.36% 72
2019
Q2 		$27.2M Buy
322,814
+106,796
+49% +$8.77M 0.34% 80
2019
Q1 		$19M Buy
216,018
+168,394
+354% +$14.1M 0.24% 93
2018
Q4 		$3.4M Buy
47,624
+47,554
+67,934% +$4.56M 0.05% 150
2018
Q3 		$9K Hold
70
– – ﹤0.01% 672
2018
Q2 		$7K Buy
+70
New +$6.27K ﹤0.01% 564

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return

Capital Bank & Trust's NBIX Position: Q3 2021 in Review

Capital Bank & Trust sold out of Neurocrine Biosciences (NBIX) in Q3 2021, closing a stake of 119,922 shares — an estimated $11.7M sold.

Capital Bank & Trust first reported a position in NBIX in Q2 2018 and held it in 13 quarters. The position peaked at $34M in Q2 2020. 396 funds tracked by Wall St. Rank hold NBIX as of Q3 2021.

  • Capital Bank & Trust reported no remaining Neurocrine Biosciences position as of Q3 2021 after selling out during the quarter.
  • Capital Bank & Trust sold 119,922 Neurocrine Biosciences shares in Q3 2021, an estimated $11.7M.
  • Capital Bank & Trust first reported a position in Neurocrine Biosciences in Q2 2018 and held it in 13 quarters.
  • Capital Bank & Trust's Neurocrine Biosciences position peaked at $34M in Q2 2020.
  • 396 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2021.

Based on Capital Bank & Trust's 13F filing for Q3 2021, filed 15 Nov 2021.